skip to main content

HIV — SCE Infectious Diseases MCQ

Instant feedback + full explanation. One question, done properly.

HardHIV MedicineHIVSCE Infectious Diseases

A treatment-naive adult has HIV-1 RNA 620,000 copies/mL, CD4 170 cells/µL, wild-type genotype, negative HBsAg and anti-HBc, and normal renal function. Which single-tablet regimen is a preferred BHIVA initial option without the viral-load restrictions of rilpivirine-based therapy?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — Bictegravir/tenofovir alafenamide/emtricitabine

BHIVA includes bictegravir with tenofovir plus emtricitabine among preferred initial regimens. Rilpivirine-based initial therapy is unsuitable at high viral load and low CD4; protease-inhibitor monotherapy is not recommended. Abacavir was removed from routine first-line recommendations in the 2025 interim update. The original item offered both TAF/FTC/DTG and TAF/FTC/BIC, making two answers correct.

Reference: BHIVA ART guideline: https://bhiva.org/clinical-guideline/hiv-1-treatment-guidelines/